Northwestern University was awarded more than $50 million for a five-year precision medicine grant as part of a landmark longitudinal research effort that aims to engage 1 million or more U.S. participants to improve disease prevention and treatment measures based on individual differences in lifestyle, environment and genetics. “The big excitement here is the opportunity to improve the way we predict, prevent and eventually treat disease.” Said Philip Greenland, MD, the Harry W. Dingman Professor of Cardiology and a principal investigator of the new award. “Just the scope of it – 1 million people – is beyond anything that anybody in the U.S. has ever done. This could be a game changer.”
1 Comment
“In a feat unmatched by any other United States hospital, Northwestern Memorial Hospital is ranked first for survival of patients suffering heart failure and second for survival of patients with heart attack and stroke, the three most common and dire cardiovascular health threats.
According to Medicare data from July 2012 through June 2015, the most recent data available, Northwestern Memorial Hospital was:
All figures are for 30-day time periods for Medicare patients, the common standard for hospital quality data.” Excerpts from: CHICAGO, Jan. 24, 2017 /PRNewswire-USNewswire/ To view the full article/original version in PR Newswire, visit: http://www.prnewswire.com/news-releases/northwestern-memorial-hospital-best-in-united-states-for-heart-attack-stroke-and-heart-failure-survival-300395842.html SOURCE Northwestern Medicine Northwestern Medicine welcomes Dr. Roger Stupp to the Northwestern Brain Tumor Institute and the Division of Neuro-Oncology in the Department of Neurology to help advance efforts to treat complex brain tumors medically. Y90 radioembolization could potentially have a role in converting liver cancers from unresectable to resectable, Dr. Riad Salem (Northwestern Medicine) says. One option for the treatment of liver cancer is a liver transplant. However, far more patients need liver transplants than there are livers, he says. "So we need to figure out ways to make people who are unresectable resectable and cure them without a transplant."
One possibility is with a radiation lobectomy, Dr. Salem says. "Radiation lobectomy means taking advantage of Y90 to treat the tumor and hypertrophy of what remains of the liver after resection. Our tools to make that happen in the past have been limited, but Y90 has changed that paradigm completely. We now are able to potentially resect and cure people that four months before were told, 'You're unresectable and incurable. That's all there is.' This is very, very exciting." A preliminary study published in the Journal of Surgical Oncology in July 2016 found that radiation lobectomy was a safe and effective method to achieve remnant liver cell enlargement while providing tumor control. Radioembolization with Y90 may also have a role in non cancer treatments. Salem and his colleagues recently started an industry-sponsored trial of radioembolization to treat enlarged spleens. "People with chronic liver disease often develop large spleens from portal hypertension," he says, adding that enlarged spleens cause low platelet counts, which can lead to any of a number of downstream health effects. One way to deal with the problem is to try to kill part of the spleen by scarring it with radiation. "If I can radiate part of the spleen and scar it down, it will metabolize fewer platelets, and the patient's platelet count will increase," Salem says. The study was approved in November 2016 and is currently enrolling patients.” Excerpts from: Radiology Today February 2017 Vol. 18 No. 2 P.18 to view the full article/original version in Radiology Today, visit: http://www.radiologytoday.net/archive/rt0217p18.shtml |
ArchivesCategories |